Genomics & CRISPR Market to Surge to USD 134 Billion by 2035, Driven by Advancements in Gene Editing

According to the MarketGenics report, the global genomics & CRISPR market is projected to expand from USD 27.4 billion in 2025 to ~USD 134 billion by 2035, registering a CAGR of 17.2%, the highest during the forecast period. The global Genomics and CRISPR industry is one of the most disruptive fields in life sciences, combining the high-level sequencing, bioinformatics, and gene-editing technologies in order to make precision medicine, agricultural innovation, and therapeutic development faster.

Genomics allows studying of genetic data in large scale to gain insight into the mechanism of diseases, to facilitate personalized medicine, and drug discovery, whereas CRISPR has already transformed genome editing by offering a precise, efficient and cost-effective way of modifying DNA. Collectively, these technologies are disrupting the domains of healthcare, biotechnology, and agriculture, making it easier to create gene therapies, diagnostic devices and genetically modified crops.

Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Genomics & CRISPR Market Research Report: https://marketgenics.co/press-releases/genomics-crispr-market-59691

Key Driver, Restraint, and Growth Opportunity Shaping the Global Genomics & CRISPR Market

The combination of genomics and CRISPR technologies has revolutionized the drug discovery process by allowing more precise and rapid identification and confirmation of therapeutic targets that result in the expansion of genomics and CRISPR market. Genomic data can enable researchers to comprehend the genetic foundations of diseases, novel biomarkers, and drug responses and CRISPR-based technologies can enable direct functional investigations by editing or silencing particular genes in order to understand their atomic role in pathways of disease. This speeds up preclinical developments, lowers the development expenses, and increases the chances of drugs candidates of the development passing on to clinical trials.

Advanced genomic and gene-editing therapies are very specific in their production, and facilities, personnel, and high-quality standards are required, which makes the mass produced costly and time-intensive. Stability, purity and consistency of biological materials like viral vectors, CRISPR components or engineered cells are technically challenging to maintain. Also, the absence of unified production guidelines and the shortage of quality raw materials also limit scalability. Such aspects raise the cost of production, the duration of development and load-bearing the process of its commercial-scale implementation, limiting the affordability and accessibility of these therapies to more patients.

To know more about the Genomics & CRISPR Market - Download our Sample Report: https://marketgenics.co/download-report-sample/genomics-crispr-market-59691

Regional Analysis of Global Genomics & CRISPR Market

The genomics and CRISPR market in North America is regarded as the most promising in the world with an effective ecosystem of research excellence, funding resources, and commercial innovation. They include the presence of major players in the market, as well as leading academic institutions that lead the research in gene-editing in the region. Strong NIH and government funding schemes such as the Somatic Cell Genome Editing (SCGE) project keep pace with innovation in the development of genome editing technologies and delivery platforms. Moreover, the large number of using precision medicine and the increasing investment of venture capital firms and the positive regulatory and intellectual property environment reinforce the leadership in North America.

The Asia Pacific region will grow the largest in genomics and CRISPR market because of the increasing number of investments in biotechnology, increase in healthcare expenditure, rise in demand on newer therapeutics, increase in incidence of chronic and lifestyle diseases, and the number of clinical research systems in countries such as China, Japan and South Korea. In addition, the presence of positive government programs and collaboration between local biotech companies and foreign drug manufacturers are also leading to the development of the market in the region.

Prominent players operating in the global genomics & CRISPR market are Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Cellecta, CRISPR Therapeutics, Danaher Corporation, Editas Medicine, GenScript Biotech, Horizon Discovery (Revvity), Illumina, Integrated DNA Technologies (IDT), Intellia Therapeutics, Lonza Group, Merck KGaA, New England Biolabs, OriGene Technologies, PerkinElmer, Qiagen, Synthego, Takara Bio, Thermo Fisher Scientific, and Other Key Players.

Buy Now: https://marketgenics.co/buy/genomics-crispr-market-59691

Recent Development and Strategic Overview:

In June 2025, Eli Lilly and Company said it was buying in the USD 1.3 billion Verve Therapeutics, a Boston-based developer of gene-editing medicines to treat cardiovascular disease. Verve Lead program, VERVE-102 is an in vivo therapy against the PCSK9 gene to achieve a lifelong reduction of cardiovascular risk with a single dose, which is a strategic growth of Lilly in the field of genomics and therapeutic gene-based therapy.

In May 2025, Regeneron Pharmaceuticals announced it acquired 23andMe with a USD 256 million bid, having access to one of the largest human genomic databases in the world of more than 14 million people. The acquisition proposes to combine consumer genetics information with the findings by Regeneron to hasten gene discovery and genomics-based therapeutic development and enhance its presence in precision medicine.

Get a preview of our Genomics & CRISPR Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/genomics-crispr-market-59691

Key Trend: Rising Focus on CRISPR-Based Agricultural Biotechnology Enhances Market Diversification

The growing development of CRISPR technology in agricultural biotechnology is a defining trend that is changing the international market of Genomics and CRISPR. An example is that under the May 2025, India was the first to develop genome-edited rice, with the release of DRR Rice 100 (Kamala) and Pusa DST Rice 1 designed by ICAR using CRISPR-Cas technology. These varieties can be characterized by better yield, resistance to climatic conditions, and the use of less water, which was unveiled by the Union Agriculture Minister, Shri Shivraj Singh Chouhan.

With climate change, food insecurity and pathogen resistance escalating, gene-editing technology such as CRISPR is being used to produce more robust, high-profitable, and nutritionally enriched foods. An example of this is In February 2025, Corteva Agriscience collaborated with the International Maize and Wheat Improvement Center (CIMMYT) to create CRISPR-edited maize resistant to maize lethal necrosis disease which has reduced yields in sub-Saharan Africa by up to 90%. The project is expected to develop climate and disease resistant corn hybrids in order to enhance the food security in the region.

Application of CRISPR in agriculture is accelerating innovation in crops, improving food security in the world, and diversifying the Genomics & CRISPR market to sustainable agricultural biotechnology rather than just in healthcare.

Contact:

Mr. Debashish Roy

MarketGenics India Pvt. Ltd.

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

About Us

MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.

We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.

This release was published on openPR.